Monitor for additional insider selling in the next 30 days — while this cluster is within normal ranges, concentrated C-suite sales could signal caution ahead of earnings or regulatory decisions. The non-cash awards are standard compensation and not a concern.
Price Chart
Executive Summary
Two senior executives at BioMarin Pharmaceutical sold shares in the past week, with total open-market proceeds of approximately $1.98 million. The sales represent modest insider selling, while two other executives received non-cash stock awards. The selling activity is notable but not extreme relative to the company's $11.8B market cap.
Key Financial Metrics
Key Facts
- EVP and Chief Legal Officer George Eric Davis sold 26,061 shares for $1.60M in open-market transactions.
- EVP and Chief R&D Officer Gregory Friberg sold 6,326 shares for $381,937.
- Two other executives (Davis and CFO Brian Mueller) received non-cash stock awards totaling 12,860 shares with no monetary value exchanged.
- Total open-market selling value: $1.98 million (0.017% of $11.8B market cap).
- All transactions occurred within a 2-day window, indicating a clustered but routine insider activity period.
Financial Impact
$1.98 million in open-market sales by two C-suite executives; non-cash awards add no financial value.
Risk Factors
- Perception of insider pessimism if no offsetting buy activity follows.
- Potential for negative sentiment if selling continues ahead of key catalysts (e.g., FDA decisions).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (4 trades, 7d window) | cluster-BMRN-1772156374596 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $64.45 $63.94 | ▼ −0.79% | ▼ −1.61% | $57.72 (−10.43%) |
Sep 14, 2026 18d ago | 8-K | $66.41 $64.06 | ▼ −3.54% | ▼ −3.65% | $57.72 (−13.08%) |
Sep 1, 2026 4w ago | 8-K | $64.84 $64.41 | ▼ −0.66% | ▼ −0.74% | $57.72 (−10.97%) |
Sep 1, 2026 4w ago | Press Release | $64.84 $64.41 | ▼ −0.66% | ▼ −0.74% | $57.72 (−10.97%) |
Aug 31, 2026 4w ago | 8-K | $65.23 $64.63 | ▼ −0.92% | ▼ −0.78% | $57.72 (−11.51%) |
Aug 18, 2026 6w ago | 8-K | $66.99 $66.12 | ▼ −1.30% | ▼ −1.10% | $57.72 (−13.83%) |
Jun 4, 2026 17w ago | 8-K | $56.77 $55.95 | ▼ −1.44% | ▼ −2.01% | $57.72 (+1.68%) |
Apr 27, 2026 22w ago | 8-K | $53.62 $55.42 | ▲ +3.36% | ▲ +2.96% | $57.72 (+7.65%) |
Apr 21, 2026 23w ago | DEFA14A | $54.16 $53.24 | ▼ −1.71% | ▼ −1.76% | $57.72 (+6.57%) |
Feb 28, 2026 30w ago | Institutional Cluster | $59.71 $60.65 | ▲ +1.57% | ▲ +2.78% | $57.72 (−3.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access